🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "major milestone" in the fight against drug-resistant strains of the pathogen, according to researchers.

An International Challenge

Gonorrhoea infections are escalating worldwide, with estimates suggesting over 82 million instances annually. Especially elevated rates are seen in the African continent and nations within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune step in the face of increasing worldwide cases, the spread of superbugs and the highly restricted available drugs at this time.”

Health officials are increasingly worried about the surge in antibiotic-resistant strains. The World Health Organization has listed it as a "high-priority threat". Recent surveillance revealed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Receive Clearance

One new antibiotic, marketed under the name a brand name, was authorized by the US FDA in December for combating gonorrhoea. This disease can lead to serious health problems, including infertility. Scientists anticipate that targeted use of this new drug will help hinder the development of resistance.

Gepotidacin, developed by the pharmaceutical company GSK, also received approval in concurrent days. This drug, which is also used to treat urinary tract infections, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment was the result of a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to develop it.

“This authorization represents a major breakthrough in the therapy of highly resistant gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Testing Data and Global Access

Based on findings detailed in a major medical journal, zoliflodacin cured more than 90% of cases of the STI. This places it at an equal footing with the typical regimen, which involves a dual-drug approach. The research involved nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the rights to license and sell the drug in a wide range of developing nations.

Medical professionals treating patients have voiced hope. Having a easy-to-administer therapy like this is seen as a "game-changer" for gonorrhoea control. This is considered crucial to alleviate the strain of the disease for people and to prevent the spread of highly drug-resistant gonorrhoea globally.